Metformin for the Treatment of mCRC Patients Undergoing FOLFIRI Plus Target Therapy
Status:
RECRUITING
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
To investigate progression-free survival (PFS) in patients with metastatic colorectal cancer treated with chemotherapy FOLFIRI monotherapy or chemotherapy FOLFIRI combined with Metformin
Phase:
PHASE2
Details
Lead Sponsor:
Kaohsiung Medical University Chung-Ho Memorial Hospital